La Radiologia medica · 2026
Radiation therapy and overall survival in male breast cancer: a multicenter analysis of 302 patients.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Colciago Riccardo Ray, Franco Pierfrancesco, Giandini Carlotta, Carnevale Maria Grazia, Di Cosimo Serena, Minicozzi Pamela, Manitto Rebecca, Ferrara Eleonora, Fozza Alessandra, Coco Angela, Spoto Ruggero, Dominici Luca, Marino Lorenza, Lucidi Sara, De Rose Fiorenza, Bonzano Elisabetta, Prisco Agnese, Meduri Bruno, Bertini Niccolò, Meattini Icro, Verderio Paolo, De Santis Maria Carmen
Аннотация
AIM: This multicenter study aimed to assess the efficacy and the prognostic role of adjuvant radiation therapy and other factors in a cohort of male breast cancer patients (MaBC) treated in 10 Italian centers within the Clinical Oncology Breast Cancer Group.
METHODS: This retrospective study included patients diagnosed with MaBC between 2005 and 2023. Demographic, clinical, tumor, and treatment data were retrieved from medical records. Information on treatment-related acute and late adverse events was also collected. Disease-free survival (DFS) was calculated from surgery to recurrence or last follow-up visit, overall survival (OS) from diagnosis to death or last follow-up visit.
RESULTS: Overall, 302 patients were included (median age 69). Most were diagnosed with stage I-IIIa (75%; vs 25% stage IIIb-IV), invasive ductal carcinoma (88%) and luminal-like tumors (88%). Nearly all patients underwent mastectomy (96%), 31% received adjuvant chemotherapy, 83% endocrine therapy (mainly tamoxifen), and 33% radiation therapy. At a median follow-up of 79 months, DFS and OS were significantly associated, among others, with stage (p < 0.05). In stage IIIb-IV patients, omission of radiation therapy was associated with higher recurrence risk (hazard ratio, HR = 18.8, p < 0.001) and worse OS (HR = 6.45, p < 0.001). Acute radiation therapy-related adverse events occurred in 28% of patients, mostly graded 1-2, but no severe late toxicity was observed.
CONCLUSIONS: This large retrospective cohort study showed that MaBC patients treated with multi-modality therapies achieved favorable outcomes. Specifically, radiation therapy significantly improved survival in advanced stages with low incidence of late adverse events further supporting its role in daily clinical practice.
METHODS: This retrospective study included patients diagnosed with MaBC between 2005 and 2023. Demographic, clinical, tumor, and treatment data were retrieved from medical records. Information on treatment-related acute and late adverse events was also collected. Disease-free survival (DFS) was calculated from surgery to recurrence or last follow-up visit, overall survival (OS) from diagnosis to death or last follow-up visit.
RESULTS: Overall, 302 patients were included (median age 69). Most were diagnosed with stage I-IIIa (75%; vs 25% stage IIIb-IV), invasive ductal carcinoma (88%) and luminal-like tumors (88%). Nearly all patients underwent mastectomy (96%), 31% received adjuvant chemotherapy, 83% endocrine therapy (mainly tamoxifen), and 33% radiation therapy. At a median follow-up of 79 months, DFS and OS were significantly associated, among others, with stage (p < 0.05). In stage IIIb-IV patients, omission of radiation therapy was associated with higher recurrence risk (hazard ratio, HR = 18.8, p < 0.001) and worse OS (HR = 6.45, p < 0.001). Acute radiation therapy-related adverse events occurred in 28% of patients, mostly graded 1-2, but no severe late toxicity was observed.
CONCLUSIONS: This large retrospective cohort study showed that MaBC patients treated with multi-modality therapies achieved favorable outcomes. Specifically, radiation therapy significantly improved survival in advanced stages with low incidence of late adverse events further supporting its role in daily clinical practice.